Skip to main content

Myriad Proteomics Changes Name to Prolexys Pharmaceuticals

NEW YORK, Sept. 22 (GenomeWeb News) - Myriad Proteomics said today that it has changed its name to Prolexys Pharmaceuticals to more accurately represent its strategic focus "after making the conversion from a technology-focused organization to a drug discovery company."

Prolexys plans to use information about protein interactions to discover and validate new drug targets.

"Our new name, Prolexys, culminates the organizational and strategic transformation that has occurred here," said Thomas Ingolia, president and CEO. "As we continue to obtain disease biology information through the use of high-throughput proteomics technologies, we are taking a number of pathway discoveries through the process of validation, screening, and lead compound identification."

Ingolia said the company is focusing on neurodegenerative diseases and oncology.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.